New Pill Offers Promising Weight Loss and Diabetes Management Without Common Side Effects Monday, June 15, 2026 weightloss diabetes metabolism diabetesmanagement obesity clinicaltrials beta2agonist musclehealth glp1 pharmaceuticals A groundbreaking new pill could revolutionize the treatment of diabetes and obesity by targeting metabolism directly—with fewer side effects than current therapies. Recent trial results show this innovative medication reduces … Read More
Weight Loss Drugs Linked to Lower Breast Cancer Risk, Offering New Hope for Prevention Thursday, June 4, 2026 glp1 cancer prevention breastcancer diabetes weightloss medication obesity research health A groundbreaking new study has found a notable connection between GLP-1 agonists—medications commonly prescribed for weight loss and diabetes management—and a decreased risk of breast cancer diagnosis. This discovery could … Read More
Warning: Potential Pancreatic Risks Linked to GLP-1 Weight Loss Injections Monday, November 24, 2025 glp1 tirzepatide semaglutide pancreatitis sideeffects weightloss nhs mhra medicationsafety yellowcard GLP-1 receptor agonists, such as tirzepatide (Mounjaro) and semaglutide (Wegovy), are popular injectable medications prescribed to support weight loss by reducing appetite and increasing feelings of fullness. Typically … Read More
Weight-loss jabs could 'significantly lower' risk of dementia Wednesday, June 25, 2025 semaglutide dementia ozempic wegovy diabetes alzheimers glp1 weightloss cardiovascular t2diabetes A groundbreaking study has found that semaglutide, the active ingredient in the diabetes drug Ozempic and the weight-loss injection Wegovy, may significantly reduce the risk of dementia in people with type 2 diabetes. … Read More
Weight-loss jab Mounjaro outperforms rival Wegovy in major study Sunday, May 11, 2025 mounjaro wegovy weightloss obesity tirzepatide semaglutide clinicaltrial glp1 gip diabetes A groundbreaking study has found that the weight-loss drug Mounjaro (tirzepatide) helps patients lose significantly more weight than its competitor, Wegovy (semaglutide). Presented at the European Congress on Obesity in … Read More